In 2024, Beroni Group and the School of Software, Tsinghua University officially reached a cooperation agreement to jointly develop the AI-based R&D Model. This cooperation marks the deep integration of…
Immune evasion has become one of the main obstacles in the development of tumor immunotherapy. In the field of invariant natural killer T（iNKT） cell therapy, CD1d in cancer cells is…
Recently, the research team of Beroni Group has successfully developed a technology that can transform human amniotic epithelial cells into neural stem cells. This innovative approach, which aims to generate…
In the past decade, Beroni Group has achieved many breakthrough results in the fields of biomedicine and health technology with its profound scientific research strength and forward-looking strategic vision. From…
In the field of small nucleic acid drugs for the treatment of liver cirrhosis, Beroni Pharmaceutical (Guangdong) Co., Ltd., a subsidiary of Beroni Group, has recently made a significant breakthrough.…
In October 2024, Beroni Group launched a new product - Beilemei No.5 compound probiotic freeze-dried powder, which is mainly for the population who often stay up late, work, eat and…
Liver fibrosis is caused by the continuous activation of hepatic stellate cells and the deposition of collagen in the liver after liver injury caused by various diseases such as hepatitis…
